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1. Introduction 
The aim of this chapter is to present the current state of stent-assisted techniques for the 
treatment of intracranial aneurysms. Most of the information that is presented here is based 
on recent international literature, as well as the personal experience of the authors. It is 
illustrated with diagrams of key procedures. Since it is a technical chapter, the subject will 
be discussed from an operative point of view, and the topics will be presented in the order 
in which they would probably be approached by the operator: background, indication, patient 
evaluation and preparation, equipment, operative technique, results, complications and post-operative 
management.  
2. History 
In the early years of endovascular techniques, the main method for the treatment of 
wide-neck aneurysms was surgical. Attempts at embolization presented significant risks 
of coil herniation, migration, parent artery occlusion and poor mid-term morphological 
results with high recurrence rates. A great effort has been made by engineers and 
manufacturers to develop coils that present a better arrangement inside the aneurysm 
sac and fulfil two important conditions: a good apposition with the aneurysm wall, and a 
stable three-dimensional conformation, so that loops do not herniate through the 
aneurysm neck. 
The first issue was approached by the development of coils with a geometry intended to fill 
the aneurysm sac, even if it is irregular. A good apposition with all regions of the cavity may 
improve the aneurysm embolization ratio and increase the stability of the coil mass, 
preventing migration. The second issue was approached through the development of coils 
with a memory of their three-dimensional shape, so that they may be used to create a 
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relatively predictable cage that would keep the subsequent coils inside. As one may 
imagine, the above properties are relatively antagonistic. A coil that penetrates irregular 
spaces and has a good position to the aneurysm wall is also a coil that may herniate through 
a large aneurysm neck. In this context of technical difficulty, balloon and stent-assisted 
techniques have been used to provide protection for the parent artery as well as to treat coil 
mass herniation. 
Intracranial stents also serve as scaffolding for neo-endothelization, providing additional 
reduction of the flow into the aneurysm. Consequently, their use improves intrasaccular 
thrombosis and decreases the risk of recanalization. 
Even if these concepts seem attractive, manufacturers were rapidly confronted with 
technical difficulties, such as the narrowness and fragility of the intracranial vasculature, the 
need to navigate tortuous vessels, and the obligation to provide materials that were thin 
enough so that a microcatheter could be placed simultaneously in the vasculature. 
The first case of intracranial stenting for treating a brain aneurysm was reported by 
Higashida et al. in 1997 (Higashida et al., 2005). In that occasion, the authors used a balloon-
expandable cardiac stent in combination with Guglielmi detachable coils to treat a fusiform 
aneurysm of the vertebrobasilar junction. At that time, other authors had already attempted 
the placement of stent and coils in a fusiform aneurysm in an experimental context in pigs. 
Soon after, different groups reported a number of strategies using a combination of balloon-
mounted stents and coils. In 2000, the use of stents for managing coil migration during the 
treatment of wide neck aneurysms was reported (Fessler et al., 2000, Lavine et al., 2000) and 
the case series became progressively larger. 
The first stent specifically designed for the intracranial area to obtain Food and Drug 
Administration (FDA) approval was the NeuroformTM (Boston Scientific Corporation, 
Natick, USA). The device was approved for 'humanitarian device exemption' in 2002. This 
means that its use was complicit to the additional approval of an Institutional Review Board 
and was supposed to be limited to use on no more than 4000 individuals per year in the 
United States of America (USA). 
Outside the USA, especially in Europe and in the context of clinical research, other stents 
became rapidly available. That was the case with the LeoTM (Balt, Montmorency, France), the 
first self-expanding closed cell design stent released in Europe in 2003, and then the 
EnterpriseTM (Cordis Neurovascular I., Miami Lakes, USA), which was approved by the 
FDA in the US in 2007. 
Flow diverters are the last technical advances bringing the concept of 'reverse remodeling' 
for intracranial aneurysm treatment. SilkTM (Balt, Montmorency, France) and PipelineTM 
(Chestnut Medical Technologies Incorporation, Menlo Park, CA, USA) are in this category. 
These devices are intended to exclude the aneurysm sac from the parent artery by creating 
significant flow disruption, so that blood significantly stagnates inside the aneurysm sac and 
thromboses. 
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3. Indications 
For treatment of intracranial aneurysms, stents are used mainly in two different situations: 
wide neck aneurysm and unfavourable anatomy. Wide neck aneurysm has been defined as 
a saccular aneurysm in the diameter of the neck larger than 4 mm, in which the dome–to-
neck ratio is less than 2, or in which the ASPECT ration is superior to 1.6. These 
circumstances are associated with an increased risk of coil migration and compromising of 
parent artery patency during non-assisted endovascular coiling. Both situations are not 
uncommon with large and giant sacciform aneurysms. Circumstances for unfavourable 
anatomy are MCA trifurcation, neck-to-parent artery diameter <1 and fusiform aneurysms. 
The indication stent-assisted endovascular treatment of cerebral aneurysms goes beyond 
vascular morphology. In the last few years, issues regarding patient selection have received 
progressively more attention, with the aim of reducing perioperative complications. A 
candidate for such a procedure must understand the risks and benefits, and be capable of 
following medical recommendations, especially the use of double antiplatelet therapy. As a 
consequence, any social and psychiatric conditions in which the compliance of the use of 
such medications and follow-up are significantly compromised should be considered as 
relative contra-indications.  
Caution should be taken with individuals who may need surgery or a ventricular drainage 
shortly after the aneurysm treatment - situations that are more frequent with ruptured 
aneurysms. As the use of antiplatelet medication is mandatory, significant controversy 
exists on the placement of intracranial stents in the acute phase of intracranial haemorrhage. 
If subtotal embolization of the aneurysm sac may be performed with coils only, a valuable 
strategy is to complete treatment in a different session. In such a case, stenting would be 
performed far from the subarachnoid haemorrhage. Other relative contra-indications are 
exaggerated; vessel tortuosity, significant atherosclerotic disease and coagulation disorders. 
4. Pre and per-operative evaluation 
The decision to deploy an intracranial stent is taken after considering the feasibility of 
performing the treatment without it (e.g. aneurysm coiling to be safely treatable using 
balloon remodeling techniques), or the possibility of not completing the treatment due to 
technical difficulties such as poor navigability. The diameter and length of each device is 
chosen according to the diameter of the native vessel and the extension of the pathological 
segment. 
Important issues for treatment planning are: exact aneurysm anatomical location, parent 
artery morphology and presence of side branches and perforators. These factors are studied 
on CT, MRI or DSA images before the operative procedure. The size and shape of the 
aneurysm, as well as the diameter of the neck, are recorded. The diameter of the parent 
artery is then measured, as well as the segment of the artery that will be covered by the 
stent. The operator will then be able to choose the adequate diameter and length of the 
device to use so that adequate covering of the neck can be assured. 
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The tortuosity of the parent artery and the technique for coiling (e.g. jailing, semi-jailing, 'X' 
and Y' stents, etc.) also influences the type of stent used (open cell versus closed cell, self-
expandable versus balloon-mounted, etc). It is particularly important to detect potential 
irregularities due to other vascular pathologies such as atherosclerosis or fibromuscular 
dysplasia. Part of the assessment of feasibility of the stent-assisted treatment is the study of 
branches presenting with sharp angle of bifurcation or incorporation of its origin into the 
neck of the aneurysm. Such vessels may be very difficult to catheterize. If it needs to be 
stented, this may result in a longer and more laborious procedure. If the progression of a 
microguidewire and a microcatheter inside a recurrent branch is impossible after numerous 
attempts, other treatment modalities (e.g. surgical) must be considered. As a consequence, 
the patient must be properly informed before the endovascular procedure that his or her 
treatment presents elements of technical complexity, and that endovascular treatment may 
not be feasible. 
5. Pre-operative preparation 
A baseline neurological examination is performed and neurological scores are attributed 
when applicable (e.g. modified Rankin and NIHSS score), which are useful for follow-up , 
especially for patients who have a past history of neurological disease.  
Antiplatelet agents are highly recommended in the preparation patients undergoing 
intracranial stenting. Insufficient platelet inhibition (PI) has been associated with an 
augmented risk of thrombus formation and embolic complications. As a consequence, 
patients receive either a loading-dose or a period of antiplatelet therapy.  A loading-dose of 
300 or 600 mg of clopidogrel is then administered the day before the endovascular 
treatment. Alternatively a dose of 75mg PO QD for five or more days has also been 
proposed for some authors. This is supported by both literature to date and previous 
experience in the cardiology field. 
Since double antiaggregation is recommended, administration of acethyl-salicic acid (ASA) 
is also performed perioperatively. Some authors have suggested the use of preparations of 
325mg or more for three or more days before the procedure, concomitant with clopidogrel. 
Other teams have preferred to administer a single intravenous bolus of 250-500 mg of 
injectable ASA at the moment of the endovascular procedure. This presents the advantage of 
avoiding the use of double antiaggregation in the pre-operative period, in which the 
aneurysm is not yet secured. However, injectable preparations are not available in all 
countries worldwide. 
Whilst ASA resistance seems relatively uncommon, clopidogrel resistance seems to be 
frequent. The prevalence of low-response to this drug varies from 28% to 66% in literature. 
Little data is available specifically for patients undergoing stent-assisted treatment of 
intracranial aneurysms, but thromboembolic adverse events do seem highly concentrated in 
the low responder group. Some authors have consequently recommended a level of at least 
40% of platelet inhibition.  
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Individual response to clopidogrel may be evaluated using different techniques. Recently, 
point-of-care assays have been commercially available, allowing practitioners to perform 
prompt measurements pre-operatively. The level of PI is now routinely assessed before 
intracranial stenting in a number of centers. In selected cases, the doses of antiplatelet agents 
might be adapted in order to achieve the desired levels. Another advantage of these point-
of-care assays is the fact that they may be performed per-operatively, so that the operator is 
informed of the percentage of antiaggregation at the moment of stent deployment.  
Such an approach requires systematic blood sampling, subsequent drug administration and 
financial investment.  At present, no prospective study assessed the potential benefits in 
achieving a level of anti-aggregation over 40% in patients undergoing intracranial 
procedures. The same applies for the assessment of the risk of hemorrhagic adverse events 
that may be related to the combination of intravenous heparin and double antiaggregation. 
We have witnessed a proliferation of portable devices and this technology is increasingly 
being used, and particularly in the cardiology field.  Different assays are now commercially 
available: VerifyNow (Accumetrics, San Diego,USA), PlateletWorks (Helena Lab.; 
Beaumont,USA), IMPACT-R (with and without ADP stimulation, DiaMed AG, Cressier sur 
Morat,Switzerland), DADE PFA collagen/ADP test (Siemens Healthcare Diagnostics 
Products, Marburg,Germany) and others. Even so, there is some evidence that only 
measurements using light transmittance aggregometry (VerifyNow and PlateletWorks) are 
significantly correlated to the occurrence of ischemic adverse events in interventional 
cardiology as suggested by the POPULAR study in 2010 (Breet et al., 2010). Other studies, 
such as the BOCLA (Neubauer et al., 2011), showed that the concept of clopidogrel 
resistance may be relative, and that more than half of poor responders may have a good 
response by increasing (two-fold) the dose.  
In the field of interventional neuroradiology, studies specifically focused on the importance 
of antiaggregation are rare. Four case series were published in 2008 (Lee et al., 2008, Muller-
Schunk et al., 2008, Pandya et al., 2008, Prabhakaran et al., 2008). Only two have studied the 
incidence of thromboembolism using techniques and different cut-offs. We recently 
performed a study on 271 procedures in which the VerifyNow assay was used and observed 
a significant association between thromboembolism and poor antiagregation. The ability to 
predict the risk of a thromboembolic event occuring does exist, but it is moderate given the 
multifactorial nature of these events. In our experience, body weight should be considered 
as an important factor to observe. After a homogenous, single loading dose of 300mg of 
clopidogrel, the prevalence of low-response (<40% of PI) is significantly lower in patients 
weighing less than 60 kilograms (43% versus 29%). If a stent has to be deployed urgently 
and the patient has not been prepared with antiplatelet agents, the risk of thromboembolic 
events may be significant, since post-operative aspirin and clopidogrel will take time to act. 
Some authors have suggested the use of a loading dose just after the procedure. Others have 
preferred to use a GPIIb/IIIa inhibitor . A bolus of 0.025 mg/Kg of intravenous abciximab 
may be administered and followed by infusion at 10 mcg/min per 12 hours. Evidently, this 
strategy should be used with caution and not as routine in view of the well-known 
hemorrhagic side effects of intravenous GPIIb-IIIa inhibitors. 
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6. Equipment 
6.1. LeoTM 
LeoTM (Balt, Montmorency, France) was the first closed-cell stent to be released in the 
market. A second generation was released thereafter as Leo+TM. This is a self-expandable 
device made of nitinol (nickeltitanium) wires with a braided design. Its main features are 
good visibility and the availability of long devices (up to 75 mm). According to the 
manufacturer, the following product characteristics should be noted:  
 Available in four nominal diameters: 2.5, 3.5, 4.5 and 5.5 mm, for vessels from 2.0 to 6.5 
mm; 
 Available in nine lengths: 12, 18, 25, 30, 35, 40, 50, 60, 75 mm; 
 Braided design of nitinol wires; 
 Self-expandable;  
 Good wall apposition; 
 Very good visibility; 
 Significant shortening after deployment;  
 Retrievable up to its 90% deployment; 
 Equipped with a double helix radio-opaque, easily visible strands; 
 Equipped with delivery microguidewire with a radio-opaque distal tip; 
 Compatible and recommended to be delivered with a Vasco+ microcatheter; 
 Recommended to be used in a triaxial system with a distal access system 6F Fargo-
Fargomax. 
6.2. NeuroformTM 
The first version of the Neuroform stent was approved in 2002 for the treatment of wide-
neck, intracranial aneurysms. It was designed for vessels with diameters from 2 to 4.5 mm. It 
was the first self-expandable device specifically designed for assisting the treatment of brain 
aneurysms with coils. Made of nitinol, the Neuroform stent has an open-cell design. In its 
first version, a low radial force resulted in a number of cases of inadequate support for the 
coil mass within the aneurysm and technical problems such as stent migration. The 
Neuroform2 stent was launched in 2003 and the Neuroform3 in 2005. According to the 
manufacturer, the following product characteristics should be noted:  
 Available in a range of sizes from 10 to 30 mm in length; 
 Available in a range of diameters from 2.5 to 4.5 mm; 
 Open cell geometry;  
 Minimal shortening after deployment; 
 Self-expandable;  
 Flexibility and conformable in tortuous distal anatomy; 
 Capable of apposition in tapered vessels; 
 Interstices of 2–2.5 F (<1mm), allowing the positioning of a microcatheter through the 
stent; 
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 Proximal and distal stent markers 
 Thin mesh; 
 Minimal radial force; 
 Not retrievable. 
 Equipped with 131cm delivery microcatheter (3F proximal, 2.8F distal)  
 Compatible and more appropriate for use with 0.014" Transend 300 Floppy 
microguidewire 
 Equipped with a 150cm (2F) stabilizer (pusher) catheter with a marker band at the distal 
tip that indicates the proximity of the stabilizer catheter to the proximal end of the stent.  
In 2010, the fourth version of the Neuroform stent was released: Neuroform EZTM. This 
newest version eliminated the need for an exchange maneuver using a 3m microguidewire. 
It may be delivered using a standard 3F microcatheter. As a consequence, the following 
features should be noted:  
 Equipped with a Neuro Renegade™ Hi-Flo™ Microcatheter for deployment (total 
usable length 150cm, flexible tip length 10 cm) 
 Equipped with a 185cm stainless stent delivery wire with a radio-opaque 19mm 45º pre-
shaped distal tip and two radio-opaque positioning bumpers, one proximal, the other 
distal to the stent. 
6.3. EnterpriseTM 
The Cordis Enterprise Vascular Reconstruction Device and Delivery System consists of a 
self-expanding closed-cell stent and a delivery system. Its design is that of tubular mesh 
made of nitinol. The delivery system is composed of a delivery wire that acts also as a 
pusher. A major characteristic of this device is its easy placement, with good wall apposition 
and excellent support of the coil mass. A partially deployed device can be recaptured once 
and redeployed. A disadvantage of the delivery system is the absence of a very long 
microguidewire distal to the parent artery. In the context of very tortuous vessels, this may 
be a factor of instability during deployment. According to the manufacturer, the following 
product characteristics should be noted:  
 Available in one diameter, 4.5 mm and can be used in vessels from 2.5 to 4 mm; 
 Available in four lengths: 14, 22, 28, and 37 mm; 
 Closed-cell geometry; 
 Self-expandable;  
 Good wall apposition; 
 May present significant shortening after deployment, from 1.1 to 4.7mm, depending on 
the length of the stent and the diameter of the parent vessel;  
 Proximal and distal stent markers; 
 Equipped with a delivery wire with three radio-opaque segments (distal, at the tip of 
the wire; intermediate, long radio-opaque segment for stent positioning; and proximal 
marker, just before the proximal stent markers) 
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 Retrievable once, if the proximal end of the stent-positioning marker the (intermediate 
marker on the delivery wire) is not beyond the distal microcatheter markerband. 
 Compatible and recommended with a 0.021 Prowler Select Plus Infusion Catheter, 
positioned at least 12 mm beyond aneurysm neck before stent delivery. 
6.4. Solitaire ABTM 
The Solitaire AB (aneurysm bridging) Neurovascular remodeling Device (ev3 Cooperate, 
Plymouth, USA) is the first fully deployable and retrievable device for assisting intracranial 
aneurysm embolization with coils. It is a nitinol self-expanding stent that can be delivered 
and deployed by a single operator. The stent works with an open longitudinal split and is 
fixed to its pusher. There is no guidewire beyond the distal markers. It can be detached 
electrolytically using a dedicated detachment system. According to the manufacturer, the 
following product characteristics should be noted:  
 Available in two diameters, 4mm for vessels from 3 to 4mm, and 6 mm for vessels from 
5 to 6mm. Since recently, a new 3mm version is also available. 
 Available in three lengths: 15 (only with 4mm diameter), 20 (both 4 and 6 mm diameter) 
and 30mm (only with 6 mm diameter); 
 Closed-cell geometry; 
 Self-expandable;  
 Presence of a longitudinal split with overlapping of the stent cells, depending on the 
diameter of the parent vessel; 
 Good wall apposition; 
 High cell deformation resistance; 
 Presents significant shortening after deployment, depending on the length of the stent 
and the diameter of the parent vessel;  
 One Proximal and three distal stent markers; 
 Equipped with a delivery wire, with a detachment zone just before the proximal 
marker; 
 Can be retrieved and repositioned before detachment, even when fully deployed; 
 Compatible and recommended with a Rebar 18-27 Microcatheter (*but also compatible 
with a 0.021 Prowler Select Plus Infusion Catheter). 
6.5. PharosTM 
The Pharos stent (Micrus, San Jose, USA) was launched in 2006 in Europe for the treatment 
of ischemic disease. The Pharos Vitesse stent is the second generation of this balloon-
expandable stent for both intracranial ischemic stenosis and wide-neck aneurysm treatment. 
It is a rapid exchange balloon-delivered device, which enables the operator to deliver and 
deploy the stent in one step. Made of cobalt chromium, the stent is opened by the radial 
force of the balloon. There is no self-expansion of the device. According to the manufacturer, 
the following product characteristics should be noted:  
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 Available in eight diameters: 2, 2,5, 2,75, 3, 3,5, 4, 4,5 and 5 mm, for vessels from 2 to 5 
mm; 
 Available in six lengths: 8, 10, 13, 15, 18 and 20 mm; 
 Double helix geometry with thin struts (60 micra); 
 Not self-expandable;  
 Good wall apposition; 
 High radial force 
 Good visibility; 
 Compatible with a 0.014" microguidewire 
 Very low shortening after deployment (<1%);  
 Proximal and distal stent markers; 
6.6. LVISTM 
The Low-profile Visualized Intraluminal Support (MicroVention Incorporation, Tustin, 
USA) is a very recent generation of devices intended for use with embolic coils, now 
available in Europe. It is a hybrid closed-cell stent in nitinol with flared ends and a double 
helix of tantalum strands to assist full-length visualization. It presents a high metal-to-
surface coverage intended to help promote neo-endothelization. However, the sliding 
design of its cells ensures the feasibility of crossing the struts with a microcatheter. 
According to the manufacturer, the following product characteristics should be noted:  
 Available in three nominal diameters, 2,5, 3.5, and 4.0 mm, respectively for vessels from 
2 to 3 mm, 2.5 to 3.5 mm and 3.5 to 4.5 mm; 
 Available in six lengths, 17 and 25 mm for the 2.5 mm diameter, 15, 25 and 41 mm for 
the 3.0 mm diameter, 35 and 49 mm for the 4.0 diameter stent; 
 Hybrid, compliant closed-cell geometry with thin struts; 
 Self-expandable;  
 Good wall apposition; 
 Flared ends; 
 Good visibility; 
 High metal-to-surface coverage; 
 Significant shortening after deployment;  
 Retrievable up to 80% deployment; 
 Proximal and distal stent markers, as well as double helix radio-opaque tantalum 
strands; 
 Equipped with delivery microguidewire with a radio-opaque distal tip; 
 Compatible with a 0.021 Headway microcatheter. 
6.7. Flow diverters 
These are braided, tubular stents with very small struts that are intended to provide 
significant flow disruption along the aneurysm neck, but allow preservation of both large 
branches and small perforators. Such devices may reduce shear stress on the aneurysm wall 
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and promote intra-aneurysmal blood stagnation and thrombosis (Pierot, 2011). Besides their 
effects on flow, these devices also provide significant scaffolding for neo-endothelization 
across the aneurysm neck. They are high-cost devices and their main characteristic is the 
very high metal-to-artery coverage in comparison to conventional stents. Two devices are 
currently available, as follows. 
6.7.1. SilkTM  
The Silk and its more recent version Silk Plus (Balt, Montmorency, France) are self 
expanding stents made of braided nitinol strands, with the following technical 
characteristics. 
 Available in eight nominal diameters: 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0 and 5.5 mm, for 
vessels from 1.5 to 5.75 mm; 
 Available in six nominal lengths, 15, 20, 25, 30, 35 and 40 mm; 
 Also available in tapered version (Tapered Silk+) in three combinations of diameters: 4.0 
mm proximal and 3.0 mm distal (30mm long), 4.5 mm proximal and 3.0 distal (25 mm 
long), 4.5 proximal and 3.5 distal (30 mm long); 
 Dense mesh geometry with very high metal-to-surface coverage; 
 High radial force (Silk Plus has 15% more radial force than Silk) thanks to a different 
strut configuration; 
 Good wall apposition; 
 Good visibility; 
 Slight flared ends 
 Double helix radio-opaque markers through the entire body of the stent, combined with 
extra Platinum small wires in the Silk Plus version, that allow visualization of the 
borders of the stent; 
 Equipped with delivery pusher/microguidewire with a radio-opaque distal tip; 
 Compatible and recommended with a Vasco+ microcatheter for delivery and a triaxial 
system with a long introducer and a distal access system 6F Fargo-Fargomax; 
 Compatible with concentric Leo+ stents for lumen reconstruction before deployment of 
Silk or Silk Plus, if needed in fusiform aneurysms. 
6.7.2. PED – Pipeline Embolisation DeviceTM 
The Pipeline Embolisation Device (ev3-MTI, Irvine, USA) is a newer, self-expanding, flexible 
device, composed of 25% platinum tungsten and 75% cobalt chromium in interwoven 
strands. According to the manufacturer, the following product characteristics should be 
noted: 
 Available in eleven nominal diameters: 2.0, 2.75, 3.0, 3.25, 3.5, 3.75, 4.0, 4.25, 4.5, 4.75 
and 5.0;  
 Available in nine nominal lengths, 10, 12, 14 , 16, 18, 20, 25, 30 and 35 mm; 
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 Dense mesh geometry with braided construction and very high metal-to-surface 
coverage, which can be customized according to the push that is imposed to the 
microcatheter (increased push narrows stent cells); 
 High radial force and flexibility, resistant to kinking; 
 Good wall apposition; 
 Uniform visibility through entire device; 
 Ability to telescope multiple devices, one inside another to create longer constructs; 
 Equipped with delivery pusher/microguidewire with a radio-opaque distal tip and a 
'capture coil' that keeps the device in contact to the guidewire until significant length is 
deployed; 
 Compatible and recommended with a 2.8F/3.2F MarksmanTM  microcatheter for 
delivery and deployment. 
6.8. Other 
It is worth noting that a number of stents that were not specifically designed for use with 
intracranial aneurysms have non-rarely been used as adjunctive devices. This situation was 
much more frequent in the early times of stent-assisted aneurysm embolization, when a 
lesser variety of devices were available. That is the case with the Jostent GraftMaster Stent 
Graft (Abbott Vascular, Redwood City, Calif), a balloon-mounted system consisting of two 
stainless steel flexible devices with an expandable layer of polytetrafluoroethylene between 
them. It was developed for use within the coronary circulation, particularly for cases of 
leakage or vessel perforation. However, cases of repair of internal carotid artery, middle 
cerebral artery and vertebral artery aneurysms were regularly reported with this system 
(Chan et al., 2004, Mehta et al., 2003, Pero et al., 2006, Saatci et al., 2004, Wang et al., 2009). 
During the advancement of neurointerventional tools for wide-neck aneurysms, several 
stents initially designed for the cervical carotid or coronary circulation were also used as 
adjunctive devices, such as WallstentTM (Boston Scientific, Natick, USA), MultilinkTM (Abbott  
Vascular, Redwood City, Calif), and others (Lavine & Meyers, 2007, Morizane et al., 2000, 
Wanke & Forsting, 2008).  
7. Operative technique 
7.1. Coiling and stenting: 'finishing stent' and 'rescue stent' 
An intracranial stent may be used at the end of an aneurysm embolization when coils have 
been used, which is particularly useful in cases in which the aneurysm neck was not fully 
respected by the coil mass, or to insure protection of the parent artery against coil migration. 
In addition, when a stent is deployed after an aneurysm coil, significant scaffolding for neo-
endothelisation is provided and an increase in pack density may be observed. This 
technique may be particularly useful for small aneurysms, in which the introduction of a 
microcatheter and repetitive manipulations may be dangerous. The coil is deployed first and 
then a preloaded stent is released, pushing the coil loop into the sac. This method has been 
also been known as a 'stent-jack' technique. 
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Figure 1. 'Finishing stent'. A, The coil mass protrudes slightly in the lumen of the parent vessel. B, The 
coils are pushed back into the aneurysm sack with a 'finishing stent'. 
When non-assisted coiling is performed, coil migration or herniation of the coil mass may be 
observed, even if the neck is not very wide. This may also be observed during balloon-
assisted embolization. If a large amount of material is present in the lumen of the parent 
artery, its patency may be threatened, or the patient may be exposed to a risk of embolic 
phenomena. In such a situation, a valuable technique can be the deployment of what is 
called a  'rescue stent', which pushes the herniated coils against the vessel wall or back 
inside the aneurysm sac. 
7.2. Stenting and coiling: crossing a deployed stent with a microcatheter 
When stent-assisted coiling is performed, the microcatheter tip may be placed inside the 
aneurysm the through the stent struts. The choice between this method and placement of 
the microcatheter before stenting depends on the operator's experience, the vascular 
morphology and aneurysm size. Placement of a microcatheter into the aneurysm is 
evidently more difficult after stenting, especially if a closed-cell device was used. In this last 
case, a thinner microcatheter may be necessary. Some practitioners prefer using a 
Neuroform stent in such situations, for the same reason. Furthermore, with a Neuroform 
stent, it is easier to regain access to the aneurysm sac in cases of microcatheter kickback into 
the parent vessel. 
If the operator experiences difficulty in penetrating the aneurysm sac, especially when the 
angle of penetration is not favorable, caution should be taken in order to avoid abrupt 
release of energy accumulated in the system, which may have disastrous consequences, 
especially with small or ruptured cerebral aneurysms. 
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Figure 2. Crossing a deployed stent with a microcatheter. A, A stent is deployed, bridging the 
aneurysm neck. B, A microcatheter is introduced into the aneurysm sac through the stent struts 
allowing treatment with coils. C, Final result, after removal of the microcatheter. 
7.3. 'Jailing' technique 
The technique of placement of the microcatheter tip inside the aneurysm before deployment 
of the stent has the advantages of being technically easier and being less susceptible to 
microcatheter kickback phenomena. However, when significant kickback occurs, it may be 
problematic to regain access to the aneurysm sac. Some authors argue that the previous 
deployment of coil loops before stent placement may be useful. The previously deployed 
coil may be used as a guidewire and allow reintroduction of the microcatheter in case of 
early kickback (Kim et al., 2011). 
7.4. 'Semi-jailing' technique 
In this technique, a stent is partially deployed in front of the aneurysm neck to act as a 
remodeling device. For this, the operator chooses a retrievable device such as Solitaire AB or 
Enterprise (retrievable if the proximal end intermediate marker of the delivery wire is not 
beyond the distal microcatheter markerband). This technique presents several advantages: 
the possibility to regain access to the aneurysm sac in case of kickback by a slight 
repositioning of the stent; the absence of blood flow arrest as observed with balloon-
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remodeling techniques; the possibility to chose to either retrieve or definitely deploy the 
stent after coiling; and the possibility of not using double antiplatelet treatment if the stent is 
retrieved at the end of the procedure. 
 
Figure 3. The 'jailing technique'. A, A microcatheter is positioned inside the aneurysm. B, The stent is 
deployed. C, The aneurysm is treated with coils. D, Final result. 
 
Figure 4. The 'semi-jailing' technique with a partially deployed stent. 
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7.5. 'Y' and 'X' stenting 
If one stent is not able to adequately protect the parent artery or a bifurcation branch, a 
possible solution is the deployment of two devices in a 'Y' configuration. A first stent is 
deployed in one of the branches, preferably an open-cell device. A microcatheter is then 
navigated into the other branch and a second stent is released. Another possibility is to place 
both stents in a parallel configuration, without crossing the first one. For confluent vessels 
such as in the anterior communicating territory, crossing stents are also possible, what has 
been called an 'X' configuration (Kim et al., 2011).  
 
Figure 5. The 'Y' Stent Technique. A, A basilar tip aneurysm. B, An open-cell stent is deployed into the 
basilar artery and right posterior cerebral artery, but is not sufficient to provide adequate protection 
against coil herniation or migration. C. A second (closed-cell) stent is placed in the basilar artery 
(concentric to the first stent) and left posterior cerebral artery. D. A microcatheter is positioned inside 
the aneurysm sac, which is treated with coils. 
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7.6. Temporary stenting (Solitaire ABTM) 
Similar to the 'semi-jailing' technique, temporary stenting consists of using a stent as a 
remodeling device, with full retrieval of the device at the end of the procedure. Up to date, 
only stents from the Solitaire group may be retrieved after full deployment. It is worth 
noting that with this kind of stent (but not exclusive to this brand) the use of a dynamic 
push in the delivery wire increases notoriously the apposition to the vascular walls, an effect 
that is important to remember when using this device as a remodeling tool. 
 
Figure 6. Temporary stenting with a Solitaire AB device. A, The microcatheter is positioned inside the 
aneurysm. B, The microcatheter is 'jailed' in the aneurysm by the Solitaire AB stent, which is completely 
deployed but not detached. C, The aneurysm is treated with coils. D, The Solitaire AB device is 
retrieved. E, Final result, no stent is left in the parent vessel. 
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7.7. Flow diversion 
Even though a large part of the deployment steps are common for the majority of 
intracranial stents, the technique for flow diverters differs in some details that make the 
method more challenging. The operator must work within a technique of pushing the 
delivery microguidewire forward, of pulling the microcatheter back, and pushing the entire 
system so that the stent opening and apposition are optimal. In addition, the phenomenon 
of shortening after deployment must be taken into consideration for the adequate selection 
of the stent length.  
For the Pipeline Embolization Device, adequate pushing on the microcatheter is also 
important to release the distal extremity of the device from the capture coil that keeps it 
attached to the delivery microguidewire. In addition, forward pushing may increase mesh 
density, and accounts for the customization that is possible with this type of device. With an 
adequate push at the right site, one may deploy a PED with an increased metal-to-artery 
coverage at the aneurysm neck. 
 
Figure 7. Treatment of a cerebral aneurysm using flow diversion with a Pipeline Embolization Device. 
A, Aspect of blood flow before and after placement of the device. B, Final result with thrombosis of the 
aneurysm. Note the higher density of the mesh near the aneurysm neck, which can be obtained with 
proper deployment technique. 
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8. Results 
The morphological results on immediate and late post-operative angiograms are categorized 
according to the revised Raymond classification into 1 of the following groups: complete 
occlusion, neck remnant, and residual aneurysm. Follow-up examinations with Digital 
Substraction Angriography or Magnetic Resonance Angiograms are then scheduled at 
minimum intervals of 6, 18 and 36 months. In cases of early recanalization, a DSA would be 
preferred in order to properly assess the need for retreatment. 
The rates of complete occlusion differ significantly from the results observed on the 
immediate postoperative angiogram after stent-assisted coiling. In a recent study on the 
Neuroform Stent in our institution, we observed that the percentage of complete occlusion 
tends to stabilize after six months. However, progressive thrombosis and subsequent 
increase of the degree of aneurysm occlusion between the immediate postoperative and six-
month angiograms are observed in roughly 50% of the aneurysms treated with stent-
assisted techniques (Maldonado et al., 2010). Of 76 aneurysms studied, 31.6% were 
completely occluded in the initial embolization, 63.8 at six months and 64.7% at 18 months. 
However, in three years of follow-up, six aneurysms with an initial complete occlusion and 
five with a neck remnant recanalized. The analysis by type of coil did not demonstrate any 
association between complete occlusion and coil type. 
 
Figure 8. Endovascular treatment of a repermeabilized aneurysm of the right middle cerebral artery using 
the Neuroform Stent System. A, after initial embolization; B, repermeabilization seven months later; C, 
after re-treatment using a Neuroform stent and a 'jailing' technique; D, angiographic control 14 months 
after retreatment, showing adequate reconstruction and re-endothelization of the bifurcation zone. 
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Stents may contribute to the progression of thrombosis, independent to the size of the 
aneurysm and type of coils used. Fiorella et al (Fiorella et al., 2005) reported an improvement 
of anatomic results with progressive thrombosis in 52% of cases of patients treated with the 
Neuroform stent. Lubicz et al (Lubicz et al., 2009) observed progressive thrombosis in 53% of 
aneurysms coiled with MicroPlex bare coils or GDCs using the Leo stent. 
The overall complete occlusion rate obtained with stent-assisted coiling seems superior to 
results obtained with coils alone or other adjunctive devices in cases of large or complex 
aneurysms. Sedat et al (Sedat et al., 2009) documented 9.5% of aneurysmal regrowth at a 
mean follow-up of 42 months.  
9. Complications 
Recent case series report incidences of adverse events ranging from 8.4 to 18.9%. Risk factors 
for complications are age, presence of significant atherosclerotic disease, subarachnoid 
hemorrhage, small aneurysm and large/giant aneurysm. The most common of those adverse 
events in the peri-operative phase are navigation problems, stent misplacement, stent 
migration, vessel dissection or perforation, and thromboembolic events. 
Delayed stroke due to intrastent thrombosis or intrastent stenosis are less frequent but may 
be observed, especially in patients with irregular use of antiplatelets. In a recent study 
published by the authors on 76 aneurysms treated with a Neuroform Stent-assisted 
technique, a five-month delayed symptomatic stroke and three clinically silent in-stent 
stenosis were observed. 
There is currently significant concern about the risk of delayed rupture after flow-diversion 
treatment. The exact mechanism of this adverse event is not completely understood. There 
are two main hypotheses for this phenomenon. First, the mural thrombus may act as a 
source of inflammatory substances such as proteases leading to chemical degradation and 
weakening of the aneurysm wall. Second, flow diversion may induce changes in intra-
aneurysmal flow pattern with a consequent increase in stress to areas that were not 
previously exposed. In a series of recent international cases of rupture after flow diversion, 
the following risk factors seemed to be important (Kulcsar et al., 2010):  
 Large or giant aneurysm; 
 Symptomatic aneurysm; 
 Saccular aneurysm with AR>1.6; 
 Morphologic characteristics predisposing to an inertia-driven inflow. 
10. Post-operative management 
During the procedure, patients are anticoagulated with a bolus of standard heparin (70–100 
IU/kg) followed by an intravenous drip through an automated syringe (40–60 IU/kg/h) to 
maintain an activated clotting time of 250 seconds, which may be continued for 12-24 hours. 
At the end of the procedure, they receive an IV dose of 250–500 mg of ASA unless they are 
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already using oral Aspirine. A daily dose of clopidogrel (75 mg) and ASA (75 mg) is then 
administered for two or three months. After that period, only one of those antiplatelet 
agents is continued, for a period of time that has varied in literature from three months to 
indefinitely. 
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